The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Blockade of A 2A receptors potently suppresses the metastasis of CD73 + tumors
Open accessAbstract
CD73 inhibits antitumor immunity through the activation of adenosine receptors expressed on multiple immune subsets. CD73 also enhances tumor metastasis, although the nature of the immune subsets and adenosine receptor subtypes involved in this process are largely unknown. In this study, we revealed that A 2A /A 2B receptor antagonists were effective in reducing the metastasis of tumors expressing CD73 endogenously (4T1.2 breast tumors) and when CD73 was ectopically expressed (B16F10 melanoma). A 2A −/− mice were strongly protected against tumor metastasis, indicating that host A 2A receptors enhanced tumor metastasis. A 2A blockade enhanced natural killer (NK) cell maturation and cytotoxic function in vitro, reduced metastasis in a perforin-dependent manner, and enhanced NK cell expression of granzyme B in vivo, strongly suggesting that the antimetastatic effect of A 2A blockade was due to enhanced NK cell function. Interestingly, A 2B blockade had no effect on NK cell cytotoxicity, indicating that an NK cell-independent mechanism also contributed to the increased metastasis of CD73 + tumors. Our results thus revealed that CD73 promotes tumor metastasis through multiple mechanisms, including suppression of NK cell function. Furthermore, our data strongly suggest that A 2A or A 2B antagonists may be useful for the treatment of metastatic disease. Overall, our study has potential therapeutic implications given that A 2A /A 2B receptor antagonists have already entered clinical trials in other therapeutic settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“I is now well-established that tumors use numerous immunosuppressive mechanisms to facilitate tumor growth (1, 2).”
BackgroundSelf-citationAdaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Self-citationA2A adenosine receptor protects tumors from antitumor T cells
Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D., Wong, M. K. K., Huang, X., Caldwell, S., Liu, K., Smith, P., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605251103 · Cited by 1,065
Adenosine receptors as drug targets — what are the challenges?
Chen, J.-F., Eltzschig, H. K., & Fredholm, B. B. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3955 · Cited by 895
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
Stagg, J., Divisekera, U., McLaughlin, N., Sharkey, J., Pommey, S., Denoyer, D., Dwyer, K. M., & Smyth, M. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908801107 · Cited by 572
Self-citationCD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
Loi, S., Pommey, S., Haibe-Kains, B., Beavis, P. A., Darcy, P. K., Smyth, M. J., & Stagg, J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222251110 · Cited by 492
Self-citationJin, D., Fan, J., Wang, L., Thompson, L. F., Liu, A., Daniel, B. J., Shin, T., Curiel, T. J., & Zhang, B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3109 · Cited by 432
Adenosine receptors in regulation of dendritic cell differentiation and function
Novitskiy, S. V., Ryzhov, S., Zaynagetdinov, R., Goldstein, A. E., Huang, Y., Tikhomirov, O. Y., Blackburn, M. R., Biaggioni, I., Carbone, D. P., Feoktistov, I., et al. (2008) · Blood · doi:10.1182/blood-2008-02-136325 · Cited by 430
CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis
Stagg, J., Divisekera, U., Duret, H., Sparwasser, T., Teng, M. W. L., Darcy, P. K., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4246 · Cited by 401
Self-citationAdenosine promotes alternative macrophage activation via A2A and A2B receptors
Csóka, B., Selmeczy, Z., Koscsó, B., Németh, Z. H., Pacher, P., Murray, P. J., Kepka‐Lenhart, D., Jr., S. M. M., Gause, W. C., Leibovich, S. J., et al. (2012) · The FASEB Journal · doi:10.1096/fj.11-190934 · Cited by 376
CD73: a potent suppressor of antitumor immune responses
Beavis, P. A., Stagg, J., Darcy, P. K., & Smyth, M. J. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.02.009 · Cited by 355
Self-citationCD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice
Wang, L., Fan, J., Thompson, L. F., Zhang, Y., Shin, T., Curiel, T. J., & Zhang, B. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45559 · Cited by 262
Adenosinergic Regulation of the Expansion and Immunosuppressive Activity of CD11b+Gr1+ Cells
Ryzhov, S., Novitskiy, S. V., Goldstein, A. E., Biktasova, A., Blackburn, M. R., Biaggioni, I., Dikov, M. M., & Feoktistov, I. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101225 · Cited by 261
Hoskin, D., Mader, J., Furlong, S., Conrad, D., & Blay, J. (2008) · International Journal of Oncology · doi:10.3892/ijo.32.3.527 · Cited by 242
CD73: A Novel Target for Cancer Immunotherapy
Zhang, B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1544 · Cited by 236
Panther, E., Corinti, S., Idzko, M., Herouy, Y., Napp, M., la Sala, A., Girolomoni, G., & Norgauer, J. (2003) · Blood · doi:10.1182/blood-2002-07-2113 · Cited by 229
Ohta, A., Ohta, A., Madasu, M., Kini, R., Subramanian, M., Goel, N., & Sitkovsky, M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901247 · Cited by 215
CD73-Deficient Mice Are Resistant to Carcinogenesis
Stagg, J., Beavis, P. A., Divisekera, U., Liu, M. C. P., Möller, A., Darcy, P. K., & Smyth, M. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0420 · Cited by 211
Self-citationAdenosine A2B Receptor Blockade Slows Growth of Bladder and Breast Tumors
Cekic, C., Sag, D., Li, Y., Theodorescu, D., Strieter, R. M., & Linden, J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101845 · Cited by 201
Ecto-5′-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells
Wang, L., Zhou, X., Zhou, T., Ma, D., Chen, S., Zhi, X., Yin, L., Shao, Z., Ou, Z., & Zhou, P. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0292-z · Cited by 196
Kreckler, L. M., Wan, T. C., Ge, Z.-D., & Auchampach, J. A. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.096016 · Cited by 196
Häusler, S. F. M., Montalbán del Barrio, I., Strohschein, J., Anoop Chandran, P., Engel, J. B., Hönig, A., Ossadnik, M., Horn, E., Fischer, B., Krockenberger, M., et al. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1040-4 · Cited by 193
Desmet, C. J., Gallenne, T., Prieur, A., Reyal, F., Visser, N. L., Wittner, B. S., Smit, M. A., Geiger, T. R., Laoukili, J., Iskit, S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222085110 · Cited by 172
The A2B Adenosine Receptor Impairs the Maturation and Immunogenicity of Dendritic Cells
Wilson, J. M., Ross, W. G., Agbai, O. N., Frazier, R., Figler, R. A., Rieger, J. M., Linden, J. M., & Ernst, P. B. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801279 · Cited by 158
Altered purinergic signaling in CD73‐deficient mice inhibits tumor progression
Yegutkin, G. G., Marttila‐Ichihara, F., Karikoski, M., Niemelä, J., Laurila, J. P., Elima, K., Jalkanen, S., & Salmi, M. (2011) · European Journal of Immunology · doi:10.1002/eji.201041292 · Cited by 156
Airas, L. M., Hellman, J., Salmi, M., Bono, P., Puurunen, T., Smith, D. J., & Jalkanen, S. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.182.5.1603 · Cited by 147
Leth‐Larsen, R., Lund, R. R., Hansen, H. V., Lænkholm, A., Tarin, D., Jensen, O. N., & Ditzel, H. J. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800061-mcp200 · Cited by 129
Ryzhov, S. V., Zaynagetdinov, R., Goldstein, A. E., Novitskiy, S. V., Blackburn, M. R., Biaggioni, I., & Feoktistov, I. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.131540 · Cited by 114
The A2B Adenosine Receptor Promotes Th17 Differentiation via Stimulation of Dendritic Cell IL-6
Wilson, J. M., Kurtz, C. C., Black, S. G., Ross, W. G., Alam, M. S., Linden, J. M., & Ernst, P. B. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100117 · Cited by 109
Expression of ecto-5′-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma
Sądej, R., Spychała, J., & Składanowski, A. C. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000215030.69823.11 · Cited by 106
BLACK, K. J., Koller, J. M., Campbell, M. C., Gusnard, D. A., & Bandak, S. I. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.2590-10.2010 · Cited by 102
Stewart, T. J., & Abrams, S. I. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.2851 · Cited by 89
Airas, L. M., Niemelä, J., & Jalkanen, S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5411 · Cited by 84
NLRP3 promotes inflammation‐induced skin cancer but is dispensable for asbestos‐induced mesothelioma
Chow, M. T., Tschopp, J., Möller, A., & Smyth, M. J. (2012) · Immunology and Cell Biology · doi:10.1038/icb.2012.46 · Cited by 81
Self-citationA3 adenosine receptor agonist potentiates natural killer cell activity
Harish, A., Hohana, G., Fishman, P., Arnon, O., & Bar‐Yehuda, S. (2003) · International Journal of Oncology · doi:10.3892/ijo.23.4.1245 · Cited by 77
CD73 mediates adhesion of B cells to follicular dendritic cells
Airas, L. M., & Jalkanen, S. (1996) · Blood · doi:10.1182/blood.v88.5.1755.1755 · Cited by 59
Dieckhoff, J., Mollenhauer, J. A., Kühl, U., Niggemeyer, B., von der Mark, K., & Mannherz, H. G. (1986) · FEBS Letters · doi:10.1016/0014-5793(86)80135-1 · Cited by 57
Gene expression profiling of tumor xenografts: In vivo analysis of organ‐specific metastasis
Lee, H.-R., Lin, E. C. K., Liu, L., & Smith, J. W. (2003) · International Journal of Cancer · doi:10.1002/ijc.11428 · Cited by 50
Long‐term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease
Factor, S. A., WOLSKI, K. P., Togasaki, D. M., Huyck, S. B., Cantillon, M., Ho, T. W., Hauser, R. A., & Pourcher, E. (2013) · Movement Disorders · doi:10.1002/mds.25395 · Cited by 45
Istradefylline for the treatment of Parkinson's disease
Park, A., & Stacy, M. A. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.643869 · Cited by 36
NK1.1+ Cells and CD8+ T Cells Mediate the Antitumor Activity of Cl-IB-MECA in a Mouse Melanoma Model
Morello, S., Sorrentino, R., Montinaro, A., Luciano, A., Maiolino, P., Ngkelo, A., Arra, C., Adcock, I. M., & Pinto, A. (2011) · Neoplasia · doi:10.1593/neo.101628 · Cited by 28
Cited by
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Self-citationImmune evasion in cancer: mechanistic basis and therapeutic strategies
Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625
Self-citationMittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
Self-citationTargeting natural killer cells in cancer immunotherapy
Guillerey, C., Huntington, N. D., & Smyth, M. J. (2016) · Nature Immunology · doi:10.1038/ni.3518 · Cited by 1,066
Self-citationCombination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
Self-citation
Metadata
- Authors
- Beavis, P. A., Divisekera, U., Paget, C., Chow, M. T., John, L. B., Devaud, C., Dwyer, K., Stagg, J., Smyth, M. J., & Darcy, P. K.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2013-08-20
- Volume
- 110
- Issue
- 36
- Pages
- 14711-14716
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2030272844
- Cited by
- 345
- References
- 41
- FWCI
- 17.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.